415 related articles for article (PubMed ID: 28079637)
1. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
[TBL] [Abstract][Full Text] [Related]
2. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma.
Hollmig ST; Rieger KE; Henderson MT; West RB; Sundram UN
Am J Dermatopathol; 2013 Apr; 35(2):176-9. PubMed ID: 23000905
[TBL] [Abstract][Full Text] [Related]
3. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
Soleymani T; Tyler Hollmig S
Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
[TBL] [Abstract][Full Text] [Related]
4. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
6. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience.
McCoppin HH; Christiansen D; Stasko T; Washington C; Martinez JC; Brown MD; Zwald FO
Dermatol Surg; 2012 Feb; 38(2):230-9. PubMed ID: 22129349
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma.
Bull C; Mirzabeigi M; Laskin W; Dubina M; Traczyc T; Guitart J; Gerami P
J Cutan Pathol; 2011 Aug; 38(8):631-5. PubMed ID: 21623867
[TBL] [Abstract][Full Text] [Related]
8. Atypical fibroxanthoma: Systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision.
Tolkachjov SN; Kelley BF; Alahdab F; Erwin PJ; Brewer JD
J Am Acad Dermatol; 2018 Nov; 79(5):929-934.e6. PubMed ID: 29981390
[TBL] [Abstract][Full Text] [Related]
9. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers.
Kuntz T; Siebdrath J; Hofmann SC; Baltaci M; Schaller J; Hellmich M; von Goltzheim LS; Assaf C; Oellig F; Michalowitz AL; Helbig D; Kreuter A
J Dtsch Dermatol Ges; 2022 Dec; 20(12):1581-1588. PubMed ID: 36442137
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Characteristics of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: A Systematic Review and Meta-Analysis.
Ørholt M; Abebe K; Aaberg F; Rasmussen LE; Daugaard S; Loya AC; Herly M; Vester-Glowinski PV
Am J Dermatopathol; 2022 Dec; 44(12):913-920. PubMed ID: 36395448
[TBL] [Abstract][Full Text] [Related]
11. Metastatic atypical fibroxanthoma.
Satter EK
Dermatol Online J; 2012 Sep; 18(9):3. PubMed ID: 23031370
[TBL] [Abstract][Full Text] [Related]
12. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.
Kanner WA; Brill LB; Patterson JW; Wick MR
J Cutan Pathol; 2010 Jul; 37(7):744-50. PubMed ID: 20184665
[TBL] [Abstract][Full Text] [Related]
13. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma.
Wieland CN; Dyck R; Weenig RH; Comfere NI
J Cutan Pathol; 2011 Nov; 38(11):884-8. PubMed ID: 21883368
[TBL] [Abstract][Full Text] [Related]
14. Atypical fibroxanthoma-a diagnosis of exclusion!
Tchernev G; Tronnier M; Ananiev J; Taneva T; Patterson JW; Gulubova M; Trafeli JP; Gegova A; Harrell M; Guarneri C; Wollina U; Cardoso JC; Kanazawa N; Zisova L; Forsea AM; Zouboulis CC
Wien Med Wochenschr; 2013 Aug; 163(15-16):380-6. PubMed ID: 23319144
[TBL] [Abstract][Full Text] [Related]
15. The many faces of Atypical fibroxanthoma.
Agaimy A
Semin Diagn Pathol; 2023 Jul; 40(4):306-312. PubMed ID: 37438163
[TBL] [Abstract][Full Text] [Related]
16. Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management.
Soleymani T; Aasi SZ; Novoa R; Hollmig ST
Dermatol Clin; 2019 Jul; 37(3):253-259. PubMed ID: 31084719
[TBL] [Abstract][Full Text] [Related]
17. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).
Helbig D; Ziemer M; Dippel E; Erdmann M; Hillen U; Leiter U; Mentzel T; Osterhoff G; Ugurel S; Utikal J; von Bubnoff D; Weishaupt C; Grabbe S
J Dtsch Dermatol Ges; 2022 Feb; 20(2):235-243. PubMed ID: 35099104
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Atypical Fibroxanthoma Versus Malignant Fibrous Histiocytoma.
Branch LG; Albertini JG; Leshin B
J Craniofac Surg; 2015 Jun; 26(4):e322-3. PubMed ID: 26080249
[TBL] [Abstract][Full Text] [Related]
19. Role of CD10, wide-spectrum keratin, p63, and podoplanin in the distinction of epithelioid and spindle cell tumors of the skin: an immunohistochemical study of 81 cases.
Buonaccorsi JN; Plaza JA
Am J Dermatopathol; 2012 Jun; 34(4):404-11. PubMed ID: 22257901
[TBL] [Abstract][Full Text] [Related]
20. Atypical Fibroxanthoma.
Chapman LW; Yu SS; Arron ST
Semin Cutan Med Surg; 2019 Mar; 38(1):E65-E66. PubMed ID: 31051027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
